{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T08:22:03Z","timestamp":1790324523927,"version":"4.1.0"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,11]]},"abstract":"<jats:sec>\n            <jats:title>Aims:<\/jats:title>\n            <jats:p>Secretory carcinoma (SC) is characterized by <jats:italic toggle=\"yes\">ETV6<\/jats:italic> rearrangements, most often <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion. Given its histologic overlap with other salivary gland tumors (SGTs), SCs can be difficult to diagnose without genetic confirmation. A recently developed pan\u2010TRK (tropomyosin receptor kinase) antibody shows promise for identifying tumors with <jats:italic toggle=\"yes\">NTRK<\/jats:italic> (neurotrophic tyrosine kinase receptor 3) fusions. The aim of this study was to evaluate the utility of pan\u2010TRK immunohistochemistry in distinguishing SCs from mimics and selecting patients eligible for TRK inhibitor clinical trials. We examined whole\u2010tissue sections from 111 SGTs with molecular characterization, including 26 SCs (23 with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion and 3 with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">RET<\/jats:italic> fusion detected by ligation-dependent reverse transcription-polymerase chain reaction, next-generation sequencing and 85 non-SC SGTs (no <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion). Immunohistochemistry was performed with a pan\u2010TRK rabbit monoclonal antibody. When any pan\u2010TRK staining (nuclear or cytoplasmic with any staining intensity) was considered to indicate positivity, 22 of 23 SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion (95.7%) and 33 of 85 non\u2010SC (38.8%) salivary neoplasms were positive, mainly basal cell adenoma, pleomorphic adenomas, adenoid cystic carcinomas, and epithelial-myoepithelial carcinomas. All SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">RET<\/jats:italic> fusion were entirely negative. When only nuclear pan-TRK staining with any staining intensity was considered positive, 18 of 23 SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion (78.3%) were positive, 11 among them with diffuse staining (&gt;30% of cells). All non-SCs and SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">RET<\/jats:italic> fusion were entirely negative. In comparison to molecular analysis (ligation-dependent reverse transcription-polymerase chain reaction, next-generation sequencing), nuclear pan-TRK IHC has a sensitivity of 78.3% and a specificity of 100% for diagnosing SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion, 69% and 100% for SCs (all fusions). Pan-TRK is a reasonable screening test for diagnosing SCs among SGTs when taking only nuclear staining into account. Although pan-TRK expression is not entirely sensitive for SCs, nuclear staining is highly specific for SCs with <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion. The lack of pan-TRK immunoreactivity in a subset of SCs is suggestive of atypical exons 4 to 14 or exons 5 to 14 <jats:italic toggle=\"yes\">ETV6<\/jats:italic>-<jats:italic toggle=\"yes\">NTRK3<\/jats:italic> fusion or non-<jats:italic toggle=\"yes\">NTRK<\/jats:italic> alternative fusion partners such as <jats:italic toggle=\"yes\">ETV6-RET.<\/jats:italic> Pan-TRK staining can serve as a strong diagnostic marker to distinguish SC from it mimics and to select patients eligible for TRK inhibitor clinical trials.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/pas.0000000000001718","type":"journal-article","created":{"date-parts":[[2021,4,26]],"date-time":"2021-04-26T20:25:34Z","timestamp":1619468734000},"page":"1487-1498","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":28,"title":["Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors"],"prefix":"10.1097","volume":"45","author":[{"given":"Marie","family":"Csanyi-Bastien","sequence":"first","affiliation":[{"name":"Department of Pathology, Centre Henri Becquerel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Delphine","family":"Lanic","sequence":"additional","affiliation":[{"name":"INSERM 1245, Rouen Normandy Uniiversity"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ludivine","family":"Beaussire","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Henri Becquerel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra","family":"Ferric","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Henri Becquerel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Fran\u00e7ois","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rouen University Hospital, Rouen"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Didier","family":"Meseure","sequence":"additional","affiliation":[{"name":"Platform of Experimental Pathology, Department of Diagnostic and Theranostic Medicine, Curie Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabrice","family":"Jardin","sequence":"additional","affiliation":[{"name":"INSERM 1245, Rouen Normandy Uniiversity"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Wassef","sequence":"additional","affiliation":[{"name":"Department of Pathology, Lariboisi\u00e8re Hospital, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ruminy","sequence":"additional","affiliation":[{"name":"INSERM 1245, Rouen Normandy Uniiversity"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marick","family":"La\u00e9","sequence":"additional","affiliation":[{"name":"Department of Pathology, Centre Henri Becquerel"},{"name":"INSERM 1245, Rouen Normandy Uniiversity"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,4,23]]},"reference":[{"key":"R2-20250608","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the etv6\u2010nTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Skalova","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"R3-20250608","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41571-018-0113-0","article-title":"NTRK fusion-positive cancers and TRK inhibitor therapy","volume":"15","author":"Cocco","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"key":"R4-20250608","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1097\/PAS.0000000000001065","article-title":"Salivary secretory carcinoma with a novel ETV6-MET fusion. Expanding the molecular spectrum of a recently described entity","volume":"42","author":"Rooper","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R5-20250608","first-page":"50","article-title":"Concurrent identification of novel EGFR-SEPT14 fusion and ETV6-RET fusion in secretory carcinoma of the salivary gland","volume":"10","author":"Black","year":"2019","journal-title":"Head Neck Pathol"},{"key":"R6-20250608","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/PAS.0000000000000972","article-title":"Molecular profiling of mammary analogue secretory carcinoma revealed a subset of tumors harboring a novel ETV6-RET translocation. Report of 10 cases","volume":"42","author":"Skalova","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R7-20250608","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.humpath.2018.08.011","article-title":"Novel gene fusions in secretory carcinoma of the salivary glands: enlarging the ETV6 family","volume":"83","author":"Guilmette","year":"2019","journal-title":"Hum Pathol"},{"key":"R8-20250608","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1097\/PAS.0000000000001535","article-title":"Expanding the molecular spectrum of secretory carcinoma of salivary glands with a novel VIM-RET fusion","volume":"44","author":"Sk\u00e1lov\u00e1","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R9-20250608","first-page":"1097","article-title":"Salivary secretory carcinoma harboring a novel ALK fusion: expanding the molecular characterization of carcinomas beyond the ETV6 gene","volume":"10","author":"Sasaki","year":"2020","journal-title":"Am J Surg Pathol"},{"key":"R10-20250608","doi-asserted-by":"crossref","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumor types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"issue":"suppl 2","key":"R11-20250608","doi-asserted-by":"crossref","first-page":"e000612","DOI":"10.1136\/esmoopen-2019-000612","article-title":"How I treat NTRK gene fusion-positive cancers","volume":"4","author":"Lassen","year":"2019","journal-title":"ESMO Open"},{"key":"R12-20250608","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: a multicentre, open-label, phase 1 study","volume":"5","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"R13-20250608","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacity of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"8","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"R14-20250608","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinibin patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"R15-20250608","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1097\/PAS.0000000000000911","article-title":"Pan\u2010TRK immunohistochemistry is an efficient and reliable screen for the detection of nTRK fusions","volume":"41","author":"Hechtman","year":"2017","journal-title":"Am J Surg Pathol"},{"key":"R16-20250608","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1097\/PAS.0000000000001062","article-title":"Pan\u2010TRK immunohistochemistry identifies nTRK rearrangements in pediatric mesenchymal tumors","volume":"42","author":"Rudzinski","year":"2018","journal-title":"Am J Surg Pathol"},{"key":"R17-20250608","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41379-018-0118-3","article-title":"Molecular characterization of cancers with nTRK gene fusions","volume":"32","author":"Gatalica","year":"2019","journal-title":"Mod Pathol"},{"key":"R18-20250608","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/his.13666","article-title":"Evaluation of pan-TRK immunohistochemistry in infantile fibrosarcoma, lipofibromatosis-like neural tumor and histological mimics","volume":"73","author":"Hung","year":"2018","journal-title":"Histopathology"},{"key":"R19-20250608","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1097\/PAS.0000000000001366","article-title":"Pan-TRK immunohistochemistry: a useful diagnostic adjunct for secretory carcinoma of the breast","volume":"43","author":"Harrison","year":"2019","journal-title":"Am J Surg Pathol"},{"key":"R20-20250608","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00428-019-02640-7","article-title":"Pan-TRK immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland","volume":"476","author":"Bell","year":"2020","journal-title":"Virchows Arch"},{"key":"R21-20250608","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1111\/his.13981","article-title":"Pan-TRK immunohistochemistry is a sensitive and specific ancillary tool for diagnosing secretory carcinoma of the salivary gland and detecting ETV6-NTRK3 fusion","volume":"76","author":"Xu","year":"2020","journal-title":"Histopathology"},{"key":"R22-20250608","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1111\/his.13845","article-title":"Immunohistochemistry with a pan\u2010TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma","volume":"75","author":"Hung","year":"2019","journal-title":"Histopathology"},{"key":"R23-20250608","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.humpath.2020.11.017","article-title":"Pan-Trk immunoreactivity, ETV6-NTRK3 fusion subtypes and RET rearrangement in salivary secretory carcinoma","volume":"109","author":"Yamamoto","year":"2020","journal-title":"Hum Pathol"},{"key":"R24-20250608","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/leu.2015.177","article-title":"Multiplexed targeted sequencing of recurrent fusion genes in acute leukaemia","volume":"30","author":"Ruminy","year":"2016","journal-title":"Leukemia"},{"issue":"suppl","key":"R25-20250608","doi-asserted-by":"crossref","first-page":"10568","DOI":"10.1200\/jco.2015.33.15_suppl.10568","article-title":"A new simple low-cost multiplexed targeted sequencing assay to detect recurrent fusion genes in sarcomas","volume":"33","author":"Angot","year":"2015","journal-title":"J Clin Oncol"},{"key":"R26-20250608","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/labinvest.2017.124","article-title":"Ligation-dependent RT-PCR: a new specific and low-cost technique to detect ALK, ROS, and RET rearrangements in lung adenocarcinoma","volume":"98","author":"Piton","year":"2018","journal-title":"Lab Invest"},{"key":"R27-20250608","first-page":"1338","article-title":"Ligation-dependent RT-PCR: a new specific and low-cost technique to detect gene fusion in salivary gland tumors. Abstracts from USCAP 2020: Head and Neck Pathology (1235-1315)","volume":"33","author":"Lanic","year":"2020","journal-title":"Mod Pathol"},{"key":"R28-20250608","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing algorithm for identification of patients with TRK fusion cancer","volume":"72","author":"Penault-Llorca","year":"2019","journal-title":"J Clin Pathol"},{"key":"R29-20250608","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"R30-20250608","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"R31-20250608","first-page":"1807","article-title":"Cellular localization of the Trk neurotrophin receptor family in human non-neuronal tissues","volume":"148","author":"Shibayama","year":"1996","journal-title":"Am J Pathol"},{"key":"R32-20250608","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/annonc\/mdw042","article-title":"What hides behind the MASC: clinical response and acquired resistance to entrectinib after etv6\u2010nTRK3 identification in a mammary analogue secretory carcinoma (MASC)","volume":"27","author":"Drilon","year":"2016","journal-title":"Ann Oncol"},{"key":"R33-20250608","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1158\/2159-8290.CD-16-1237","article-title":"Safety and antitumor activity of the multitargeted Pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1)","volume":"7","author":"Drilon","year":"2017","journal-title":"Cancer Discov"}],"container-title":["American Journal of Surgical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001718","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,8]],"date-time":"2025-06-08T21:05:09Z","timestamp":1749416709000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PAS.0000000000001718"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,23]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/pas.0000000000001718","relation":{},"ISSN":["0147-5185"],"issn-type":[{"value":"0147-5185","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,23]]}}}